Crowdonomics
All companies
SanMelix Laboratories logo

SanMelix Laboratories

Operating

SanMelix Laboratories, Inc.

Biotech · Hollywood, FL

Helping You Heal with Honey Our Goal is Simple, Faster and Healthier Healing

Post-money valuation
$23.9M
As of Jan 2022 · from SanMelix Laboratories Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$1,189,271
Across 2 rounds since 2019
Latest share price
$1.50
SanMelix Laboratories Common Stock 1 offering price

Financials

FY2017–FY2025 · from SEC filings · hover any figure for its source
$0
−$291K
2018
$0
−$227K
2019
$0
−$404K
2020
$53K
−$796K
2021
$50K
−$791K
2022
$8K
−$728K
2023
$8K
−$728K
2024
$49K
−$616K
2025
RevenueNet income — beside revenue when positive, below the line when a loss

Chart shows the most recent 8 fiscal years; 1 earlier year is in the table below.

Metric
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
$52,695
$50,233
$7,904
$7,904
$49,228
Cost of goods sold
$0
$0
$0
$0
$13,626
$39,039
$6,212
$4,232
$12,166
Gross margin
74%
22%
21%
46%
75%
Net income
$0
-$290,979
-$226,917
-$404,179
-$796,389
-$790,675
-$727,781
-$727,782
-$616,108
Taxes paid
$0
$0
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$298,229
$78,623
$51,318
$264,467
$339,829
$128,710
$67,201
$67,201
$26,889
Accounts receivable
$0
$0
$0
$0
$1,590
$839
$75
$75
$1,764
Total assets
$437,088
$95,038
$237,064
$460,947
$865,163
$323,674
$268,087
$268,087
$228,847
Short-term debt
$0
$4,272
$0
$0
$116,563
$150,000
$0
$0
$225,000
Long-term debt
$37,200
$0
$0
$29,744
$266,547
$219,667
$225,000
$225,000
$80,000
Total liabilities
$37,200
$4,272
$0
$29,744
$383,110
$369,667
$225,000
$225,000
$305,000
Other
Headcount
2
2
2
2
2
2
2

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$7.6M
post-money
$23.9M
post-money
Sanmelix 1
SanMelix Laboratories Common Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

SanMelix Laboratories Common Stock 1ClosedReg CF · Common Equity · via StartEngine
Raised $121.4K / $3.9MInvestors 124Post-money $23.9M
Sanmelix 1ClosedReg CF · Common Equity · via StartEngine
Raised $1.1M / $1.1MInvestors 1,727Post-money $7.6M

Team

11 people
Diana SabacinskiFounder
CPA-Chief Executive Officer /President (Director)

Mrs. Sabacinski is a Certified Public Accountant (CPA) and Certified Fraud Examiner(CFE) with more than 25 years of C-level management experience in the service, manufacturing, government contracting, and healthcare industries. She is an Entrepreneur and co-founded, co-owned, and operated a multi-location training organization, which was listed on the INC 500 Fastest Growing Companies.

Dr. Kenneth SabacinskiFounder
DPM, MHS, FACFAS-Chief Medical Officer (Director)

Dr. Sabacinski is board certified and has over 30 years’ clinical experience in Foot & Ankle medicine, surgery, and limb salvage. Dr. Sabacinski performed his internship, residency and fellowship training at the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. During his residency at the Beth Israel Deaconess Medical Center and the Joslin Diabetes Center, he was specifically trained in the treatment of acute and chronic diabetic foot ulcers. Dr. Sabacinski is the inventor of multiple advanced wound care patents, including SanMelix's BEECure™ wound care dressings.

Dr. Jason Green
Director of SanMelix Advisory Board

Dr. Jason Green, DO, FAOCD, FAAD, Board Certified Dermatologist, is the founder of Green Dermatology & Cosmetic Center in Deerfield Beach, Florida. Providing outstanding dermatological care, state-of-the-art procedures, cutting-edge technology, and personalized patient attention is his priority.

Barry Constantine
Research Scientist-Advisor

Mr. Constantine has forty 40 years healthcare industry experience with a strong history of advancement within the bio- technology and medical device sectors. Professional skill set includes corporate and division level leadership of product development and project management for early stage and mature organizations. Extensive experience in the areas of pharmaceuticals, tissue engineering, wound healing and skin care. Principal efforts have been the support to start-ups by developing products and FDA regulatory strategies including 510(k) applications.

Linda Murphy
Distribution/ Sales-Advisor

Mrs. Murphy Coordinates successful product launches with large distributors such as Amazon. She received the Gold Stevie Award for Entrepreneur of the Year by the American Business Awards and the Global CEO Excellence award. She was also named a ‘Top 40 Under 40 Rising Star’.

Marie Williams
Operations Manager

Marie Williams has 15+ years’ experience in education and healthcare. As the Operations Manager, Marie is directly responsible for ensuring the day-to-day processes at SanMelix run efficiently, while performing customer service activities, accounts receivable, billing and payroll duties.

COL (ret) George E. Peoples, MD, FACS
Advisor

Through his military career as a staff surgeon at a Level I trauma center and multiple combat deployments, Dr. Peoples is the founder of Trauma Insight. He has extensive trauma experience and has developed close relationships with some of the most prominent military and civilian trauma and critical care physicians in the country.

Ed Quilty
Director

Ed Quilty is a well accomplished senior business executive who has consistently led, built, and transformed organizations. During his career, he has been the CEO of four publicly-listed companies. Mr. Quilty currently is a Board Member and Advisor to several companies in the healthcare sector with over 25 years of Chief Executive experience in the healthcare industry – primarily in advanced wound care – with expertise in strategic planning, financing, management, and sales and marketing. Mr. Quilty has previously served as the CEO and Chairman of the Board of Derma Sciences Inc.—creator of Medihoney—(now Integra LifeSciences) for over 15 years.

Hamid Khosrowshahi
Director

FloSure Technologies was founded in 2011 by Hamid Khosrowshahi, a successful entrepreneur who has spent a career in the area of medical devices. He was the guiding hand behind the success of such products as: Exudry, Kollagen (Medifil and Skintemp), DuraGen (dural graft matrix), NeuraGen (nerve guide) and most recently the PRO series of negative pressure wound therapy pumps by Prospera.

Show 2 more people
John Kaufman
Director

Mr. Kaufman has over 40 years of management experience working with and for the Government, business startups, and large-scale manufacturing firms.

Samuel Hammer
Director

Samuel Hammer is the Managing Shareholder for Hammer Navarro and Associates, PA. Sam is a Certified Public Accountant (CPA) and Certified Chartered Global Management Accountant (CGMA) with more than 30 years of healthcare experience serving as a C-Suite Operating Executive, Board of Director and Advisor to Physicians, Employers, Payors, Hospitals, Physician Groups, Law Firms, Manufacturers and Government.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 6 of 7 annual reports (FY2019–FY2025)

1,727 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-TRMar 4, 20260001768911-26-000001
    EDGAR
  • Form C-ARMar 14, 20250001654954-25-002776
    EDGAR
  • Form C-ARMar 28, 20240001654954-24-003806
    EDGAR
  • Form C-ARMar 30, 20230001665160-23-000503
    EDGAR
  • Form C-ARMay 2, 20220001665160-22-001438
    EDGAR
  • Form C-UJan 13, 20220001665160-22-000086
    EDGAR
  • Form C-AR/ADec 30, 20210001665160-21-002425
    EDGAR
  • Form C-UDec 7, 20210001665160-21-002153
    EDGAR
Source: ManualCIK 0001768911DEShare price $1.50

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.